New PET tracer aims to spot Parkinson's protein in living brains

NCT ID NCT07348250

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This early-phase study tests a new imaging drug called [18F]MK-0947 that works with PET scans to show where a protein called α-synuclein builds up in the brain—a hallmark of Parkinson's disease. Researchers will check safety and how well the tracer works in 22 adults (some with Parkinson's, some healthy). If successful, this could lead to better tools for diagnosing and tracking Parkinson's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[18F]MK-0947 (a radioactive imaging drug for PET scans)
What this could lead to
If successful, this could lead to a new way to see Parkinson's-related protein buildup in the brain, helping doctors diagnose the disease earlier and track its progression.
What could go wrong
This is a very early, small study (22 people) focused on safety and imaging, not treatment. The tracer may not work as hoped, and results may not apply to all Parkinson's patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Invicro (dba Perceptive)

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.